{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:00:34Z","timestamp":1790402434615,"version":"4.1.0"},"reference-count":170,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CB07\/08\/0043, PI19\/00169, JR18\/00051"],"award-info":[{"award-number":["CB07\/08\/0043, PI19\/00169, JR18\/00051"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"publisher","award":["GenT CDEI-04\/20-B"],"award-info":[{"award-number":["GenT CDEI-04\/20-B"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cardiovascular disease (CVD) is the leading cause of death worldwide and is the clinical manifestation of the atherosclerosis. Elevated LDL-cholesterol levels are the first line of therapy but the increasing prevalence in type 2 diabetes mellitus (T2DM) has positioned the cardiometabolic risk as the most relevant parameter for treatment. Therefore, the control of this risk, characterized by dyslipidemia, hypertension, obesity, and insulin resistance, has become a major goal in many experimental and clinical studies in the context of CVD. In the present review, we summarized experimental studies and clinical trials of recent anti-diabetic and lipid-lowering therapies targeted to reduce CVD. Specifically, incretin-based therapies, sodium-glucose co-transporter 2 inhibitors, and proprotein convertase subtilisin kexin 9 inactivating therapies are described. Moreover, the novel molecular mechanisms explaining the CVD protection of the drugs reviewed here indicate major effects on vascular cells, inflammatory cells, and cardiomyocytes, beyond their expected anti-diabetic and lipid-lowering control. The revealed key mechanism is a prevention of acute cardiovascular events by restraining atherosclerosis at early stages, with decreased leukocyte adhesion, recruitment, and foam cell formation, and increased plaque stability and diminished necrotic core in advanced plaques. These emergent cardiometabolic therapies have a promising future to reduce CVD burden.<\/jats:p>","DOI":"10.3390\/ijms22020660","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T11:36:11Z","timestamp":1610364971000},"page":"660","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Therapies for the Treatment of Cardiovascular Disease Associated with Type 2 Diabetes and Dyslipidemia"],"prefix":"10.3390","volume":"22","author":[{"given":"Mar\u00eda","family":"Aguilar-Ballester","sequence":"first","affiliation":[{"name":"Health Research Institute Clinic Hospital of Valencia-INCLIVA, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Hurtado-Genov\u00e9s","sequence":"additional","affiliation":[{"name":"Health Research Institute Clinic Hospital of Valencia-INCLIVA, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4974-7327","authenticated-orcid":false,"given":"Alida","family":"Taberner-Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Health Research Institute Clinic Hospital of Valencia-INCLIVA, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Herrero-Cervera","sequence":"additional","affiliation":[{"name":"Health Research Institute Clinic Hospital of Valencia-INCLIVA, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6775-2034","authenticated-orcid":false,"given":"Sergio","family":"Mart\u00ednez-Herv\u00e1s","sequence":"additional","affiliation":[{"name":"Health Research Institute Clinic Hospital of Valencia-INCLIVA, 46010 Valencia, Spain"},{"name":"Endocrinology and Nutrition Service, Clinic Hospital of Valencia, 46010 Valencia, Spain"},{"name":"Department of Medicine, University of Valencia, 46010 Valencia, Spain"},{"name":"CIBERDEM (Diabetes and Associated Metabolic Diseases), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6883-3808","authenticated-orcid":false,"given":"Herminia","family":"Gonz\u00e1lez-Navarro","sequence":"additional","affiliation":[{"name":"Health Research Institute Clinic Hospital of Valencia-INCLIVA, 46010 Valencia, Spain"},{"name":"CIBERDEM (Diabetes and Associated Metabolic Diseases), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specifc mortality for 264 causes of death, 1980\u20132016: A systematic analysis for the global burden of disease study 2016","volume":"390","author":"Naghavi","year":"2017","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1: Evidence from genetic, epidemiologic, and clinical studies. A consensus statement fromthe European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American college of cardiology\/American heart association task force on practice guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.2337\/db14-1963","article-title":"Uncomplicating the macrovascular complications of diabetes: The 2014 edwin bierman award lecture","volume":"64","author":"Bornfeldt","year":"2015","journal-title":"Diabetes"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.dsx.2019.02.023","article-title":"Insulin resistance is a cardiovascular risk factor in humans","volume":"13","year":"2019","journal-title":"Diabetes Metab. Syndr. Clin. Res. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.cmet.2011.01.018","article-title":"Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle","volume":"13","author":"Kubota","year":"2011","journal-title":"Cell Metab."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/cvr\/cvu115","article-title":"Insulin resistance aggravates atherosclerosis by reducing vascular smoothmuscle cell survival and increasing CX3CL1\/CX3CR1 axis","volume":"103","author":"Piqueras","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Van Dijk, R.A., Duinisveld, A.J.F., Schaapherder, A.F., Mulder-Stapel, A., Hamming, J.F., Kuiper, J., de Boer, O.J., van der Wal, A.C., Kolodgie, F.D., and Virmani, R. (2015). A change in inflammatory footprint precedes plaque instability: A systematic evaluation of cellular aspects of the adaptive immune response in human atherosclerosis. J. Am. Heart Assoc., 4.","DOI":"10.1161\/JAHA.114.001403"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/MNH.0000000000000214","article-title":"New and old agents in the management of diabetic nephropathy","volume":"25","author":"Lytvyn","year":"2016","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1146\/annurev-med-050214-013431","article-title":"Cardiovascular effects of incretin-based therapies","volume":"67","author":"White","year":"2016","journal-title":"Annu. Rev. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2006.01.004","article-title":"The biology of incretin hormones","volume":"3","author":"Drucker","year":"2006","journal-title":"Cell Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Finan","year":"2019","journal-title":"Mol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/CIRCRESAHA.114.301958","article-title":"Cardiovascular actions of incretin-based therapies","volume":"114","author":"Ussher","year":"2014","journal-title":"Circ. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1080\/713609354","article-title":"Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV","volume":"40","author":"Lambeir","year":"2003","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.2337\/db10-1707","article-title":"Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome","volume":"60","author":"Lamers","year":"2011","journal-title":"Diabetes"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1161\/CIRCRESAHA.116.305665","article-title":"DPP4 in cardiometabolic disease: Recent insights from the laboratory and clinical trials of DPP4 inhibition","volume":"116","author":"Zhong","year":"2015","journal-title":"Circ. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-015-0294-0","article-title":"Antidiabetic treatment with gliptins: Focus on cardiovascular effects and outcomes","volume":"14","author":"Fisman","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_19","first-page":"386","article-title":"DPP4 in diabetes","volume":"6","author":"Wronkowitz","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2337\/db12-0230","article-title":"A potential role for dendritic cell\/macrophage-expressing DPP4 in obesity-induced visceral inflammation","volume":"62","author":"Zhong","year":"2013","journal-title":"Diabetes"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0008-8749(02)00010-2","article-title":"Soluble CD26\/dipeptidyl peptidase IV enhances transendothelial migration via its interaction with mannose 6-phosphate\/insulin-like growth factor II receptor","volume":"215","author":"Ikushima","year":"2002","journal-title":"Cell. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nature26138","article-title":"Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance HHS Public Access","volume":"555","author":"Ghorpade","year":"2018","journal-title":"Nature"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.2337\/dc13-0496","article-title":"Adipose dipeptidyl peptidase-4 and obesity: Correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro","volume":"36","author":"Sell","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.bbadis.2014.06.004","article-title":"Soluble DPP4 induces inflammation and proliferation of human smooth muscle cells via protease-activated receptor 2","volume":"1842","author":"Wronkowitz","year":"2014","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3389\/fendo.2012.00112","article-title":"Incretin hormones as immunomodulators of atherosclerosis","volume":"3","author":"Alonso","year":"2012","journal-title":"Front. Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Deng, X., Tavallaie, M.S., Sun, R., Wang, J., Cai, Q., Shen, J., Lei, S., Fu, L., and Jiang, F. (2020). Drug discovery approaches targeting the incretin pathway. Bioorg. Chem., 99.","DOI":"10.1016\/j.bioorg.2020.103810"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S2213-8587(17)30033-5","article-title":"Integration of recent evidence into management of patients with atherosclerotic cardiovascular disease and type 2 diabetes","volume":"5","author":"Standl","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1001\/jamacardio.2016.0103","article-title":"Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: Secondary analysis of a randomized clinical trial","volume":"1","author":"McGuire","year":"2016","journal-title":"JAMA Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1161\/CIRCULATIONAHA.118.038352","article-title":"Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA","volume":"139","author":"McGuire","year":"2019","journal-title":"Circulation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1111\/dom.12548","article-title":"Cardiovascular and heart failure safety profile of vildagliptin: A meta-analysis of 17,000 patients","volume":"17","author":"Mcinnes","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/ehjcvp\/pvv044","article-title":"Gliptins and their target dipeptidyl peptidase 4: Implications for the treatment of vascular disease","volume":"2","author":"Remm","year":"2016","journal-title":"Eur. Hear. J. Cardiovasc. Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1210\/en.2012-1855","article-title":"Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo e-deficient mice","volume":"154","author":"Ervinna","year":"2013","journal-title":"Endocrinology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bbrc.2020.01.027","article-title":"Inhibition of inflammation-mediated DPP-4 expression by linagliptin increases M2 macrophages in atherosclerotic lesions","volume":"524","author":"Nishida","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.molmet.2018.05.014","article-title":"The incretin hormone GIP is upregulated in patients with atherosclerosis and stabilizes plaques in ApoE\u2212\/\u2212 mice by blocking monocyte\/macrophage activation","volume":"14","author":"Kahles","year":"2018","journal-title":"Mol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s00125-011-2241-2","article-title":"Native incretins prevent the development of atherosclerotic lesions in apolipoprotein e knockout mice","volume":"54","author":"Nagashima","year":"2011","journal-title":"Diabetologia"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.peptides.2013.12.015","article-title":"A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis","volume":"54","author":"Tashiro","year":"2014","journal-title":"Peptides"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Bruen, R., Curley, S., Kajani, S., Crean, D., O\u2019Reilly, M.E., Lucitt, M.B., Godson, C.G., McGillicuddy, F.C., and Belton, O. (2017). Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis. Cardiovasc. Diabetol., 16.","DOI":"10.1186\/s12933-017-0626-3"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2017.07.014","article-title":"Exenatide mitigated diet-induced vascular aging and atherosclerotic plaque growth in ApoE-deficient mice under chronic stress","volume":"264","author":"Yang","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/bph.12490","article-title":"Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration","volume":"171","author":"Wang","year":"2014","journal-title":"Br. J. Pharm."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1007\/s00125-017-4330-3","article-title":"The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype","volume":"60","author":"Navarro","year":"2017","journal-title":"Diabetologia"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE\/\u2212 and LDLr\/Mice by a mechanism that includes inflammatory pathways","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1161\/CIRCULATIONAHA.111.041418","article-title":"Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis","volume":"124","author":"Shah","year":"2011","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/atv.0000615456.97862.30","article-title":"Endothelial GLP-1 (Glucagon-Like Peptide-1) receptor mediates cardiovascular protection by liraglutide in mice with experimental arterial hypertension","volume":"40","author":"Frenis","year":"2020","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.112.091215","article-title":"A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity","volume":"127","author":"Shikatani","year":"2013","journal-title":"Circulation"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2337\/db08-1193","article-title":"GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice","volume":"58","author":"Ban","year":"2009","journal-title":"Diabetes"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/1479-5876-11-84","article-title":"Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies","volume":"11","author":"Wohlfart","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/jdi.12446","article-title":"Anti-atherogenic and anti-inflammatory properties of glucagon-like peptide-1, glucose-dependent insulinotropic polypepide, and dipeptidyl peptidase-4 inhibitors in experimental animals","volume":"7","author":"Hirano","year":"2016","journal-title":"J. Diabetes Investig."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Li, J., Liu, X., Fang, Q., Ding, M., and Li, C. (2017). Liraglutide attenuates atherosclerosis via inhibiting ER-induced macrophage derived microvesicles production in T2DM rats. Diabetol. Metab. Syndr., 9.","DOI":"10.1186\/s13098-017-0289-y"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/cvr\/cvw213","article-title":"Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats","volume":"113","author":"Lim","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.metabol.2016.03.010","article-title":"Anagliptin, a dipeptidyl peptidase-4 inhibitor, decreases macrophage infiltration and suppresses atherosclerosis in aortic and coronary arteries in cholesterol-fed rabbits","volume":"65","author":"Hirano","year":"2016","journal-title":"Metabolism"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.atherosclerosis.2017.06.920","article-title":"Inhibition of plaque progression and promotion of plaque stability by glucagon-like peptide-1 receptor agonist: Serial In vivo findings from iMap-IVUS in Watanabe heritable hyperlipidemic rabbits","volume":"265","author":"Sudo","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1475-2840-13-21","article-title":"Do incretins improve endothelial function?","volume":"13","author":"Oyama","year":"2014","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/j.1476-5381.2012.02102.x","article-title":"Dipeptidyl peptidase-4 inhibitor improves neovascularization by increasing circulating endothelial progenitor cells","volume":"167","author":"Huang","year":"2012","journal-title":"Br. J. Pharm."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Akoumianakis, I., Badi, I., Douglas, G., Chuaiphichai, S., Herdman, L., Akawi, N., Margaritis, M., Antonopoulos, A.S., Oikonomou, E.K., and Psarros, C. (2020). Insulin-induced vascular redox dysregulation in human atherosclerosis is ameliorated by dipeptidyl peptidase 4 inhibition. Sci. Transl. Med., 12.","DOI":"10.1126\/scitranslmed.aav8824"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jphs.2016.12.003","article-title":"The effects of DPP-4 inhibitor on hypoxia-induced apoptosis in human umbilical vein endothelial cells","volume":"133","author":"Nagamine","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12933-019-0965-3","article-title":"Differences in lipid metabolism between anagliptin and sitagliptin in patients with type 2 diabetes on statin therapy: A secondary analysis of the REASON trial","volume":"18","author":"Chihara","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs. glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: The Carolina randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.2337\/dc20-0279","article-title":"Effects of linagliptin on cardiovascular and kidney outcomes in people with normal and reduced kidney function: Secondary analysis of the carmelina randomized trial","volume":"43","author":"Perkovic","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Angelyn Bethel, M., Mentz, R.J., Merrill, P., Buse, J.B., Chan, J.C., Goodman, S.G., Iqbal, N., Jakuboniene, N., Katona, B., and Lokhnygina, Y. (2020). Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: Insights from the EXSCEL trial. Diabetes Care, 43.","DOI":"10.2337\/dc19-1065"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1161\/CIRCULATIONAHA.118.033898","article-title":"Effect of liraglutide on cardiovascular events in patients with type 2 diabetes mellitus and polyvascular disease results of the LEADER trial","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.118.034516","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke: Post hoc analysis from the leader trial","volume":"138","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1479164118783935","article-title":"Cardiovascular outcomes in patients who experienced a myocardial infarction while treated with liraglutide versus placebo in the LEADER trial","volume":"15","author":"Nauck","year":"2018","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12933-020-01179-1","article-title":"Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: A post hoc analysis","volume":"19","author":"Dagenais","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-Like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00024677-200201020-00005","article-title":"Harnessing the Therapeutic Potential of Glucagon-Like Peptide-1: A Critical Review","volume":"1","author":"Baggio","year":"2002","journal-title":"Treat Endocrinol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Aroda, V.R. (2018). A Review of GLP-1 Receptor Agonists: Evolution and Advancement, Through the Lens of Randomised Controlled Trials. Diabetes Obes. Metab., 22\u201333.","DOI":"10.1111\/dom.13162"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The Discovery and Development of Liraglutide and Semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Nauck, M.A., Quast, D.R., Wefers, J., and Meier, J.J. (2020). GLP-1 Receptor Agonists in the Treatment of type 2 Diabetes\u2014State-of-the-Art. Mol. Metab., 101\u2013102.","DOI":"10.1016\/j.molmet.2020.101102"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s001250050903","article-title":"Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity","volume":"41","author":"Deacon","year":"1998","journal-title":"Diabetologia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.cmet.2018.10.003","article-title":"Dysregulation of glucagon secretion by hyperglycemia-induced sodium-dependent reduction of ATP production","volume":"29","author":"Knudsen","year":"2019","journal-title":"Cell Metab."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/1479164113481817","article-title":"The GLP-1 receptor agonist liraglutide inhibits progression of vascular disease via effects on atherogenesis, plaque stability and endothelial function in an ApoE\/mouse model","volume":"10","author":"Gaspari","year":"2013","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.bbrc.2012.07.086","article-title":"Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation","volume":"425","author":"Shiraishi","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/aps.2011.149","article-title":"Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells","volume":"33","author":"Ding","year":"2012","journal-title":"Acta Pharm. Sin."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10557-013-6463-z","article-title":"Glucagon-like peptide-1 receptor agonist liraglutide inhibits endothelin-1 in endothelial cell by repressing nuclear factor-kappa B activation","volume":"27","author":"Dai","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Krasner, N.M., Ido, Y., Ruderman, N.B., and Cacicedo, J.M. (2014). Glucagon-Like Peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097554"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.bbrc.2012.02.106","article-title":"Exendin-4 restores glucolipotoxicity-induced gene expression in human coronary artery endothelial cells","volume":"419","author":"Erdogdu","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Mori, Y., Matsui, T., Hirano, T., and Yamagishi, S.I. (2020). Gip as a potential therapeutic target for atherosclerotic cardiovascular disease\u2013a systematic review. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041509"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Finan, B., Ma, T., Ottaway, N., M\u00fcller, T.D., Habegger, K.M., Heppner, K.M., Kirchner, H., Holland, J., Hembree, J., and Raver, C. (2013). Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med., 5.","DOI":"10.1126\/scitranslmed.3007218"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Sachs, S., Niu, L., Geyer, P., Jall, S., Kleinert, M., Feuchtinger, A., Stemmer, K., Brielmeier, M., Finan, B., and DiMarchi, R.D. (2020). Plasma proteome profiles treatment efficacy of incretin dual agonism in diet-induced obese female and male mice. Diabetes Obes. Metab.","DOI":"10.1111\/dom.14215"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/JOE-20-0119","article-title":"Combination gut hormones: Prospects and questions for the future of obesity and diabetes therapy","volume":"246","author":"Khoo","year":"2020","journal-title":"J. Endocrinol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-015-0176-5","article-title":"Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications","volume":"14","author":"Yamagishi","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Nogi, Y., Nagashima, M., Terasaki, M., Nohtomi, K., Watanabe, T., and Hirano, T. (2012). Glucose-dependent insulinotropic polypeptide prevents the progression of macrophage-driven atherosclerosis in diabetic apolipoprotein E-null mice. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0035683"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nature09580","article-title":"The mechanism of sodium and substrate release from the binding pocket of vSGLT","volume":"468","author":"Watanabe","year":"2010","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol. Rev."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00125-018-4656-5","article-title":"Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2","volume":"61","author":"Ghezzi","year":"2018","journal-title":"Diabetologia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ki.2009.87","article-title":"Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications","volume":"75","author":"Bakris","year":"2009","journal-title":"Kidney Int."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00125-018-4654-7","article-title":"Development of SGLT1 and SGLT2 inhibitors","volume":"61","author":"Rieg","year":"2018","journal-title":"Diabetologia"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","article-title":"Correction of hyperglycemia with phlorizin normalizes tissues sensitivity to insulin in diabetic rats","volume":"79","author":"Rossetti","year":"1987","journal-title":"J. Clin. Investig."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","article-title":"T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes","volume":"48","author":"Oku","year":"1999","journal-title":"Diabetes"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/dom.13650","article-title":"A review of the mechanism of action, metabolic profile and hemodynamic effects of sodium-glucose co-transporter-2 inhibitors","volume":"21","author":"Brown","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nm.3828","article-title":"Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion","volume":"21","author":"Bonner","year":"2015","journal-title":"Nat. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1172\/JCI70704","article-title":"Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production","volume":"124","author":"Merovci","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejphar.2017.05.019","article-title":"Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice","volume":"809","author":"Tahara","year":"2017","journal-title":"Eur. J. Pharm."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Aroor, A.R., Das, N.A., Carpenter, A.J., Habibi, J., Jia, G., Ramirez-Perez, F.I., Martinez-Lemus, L., Manrique-Acevedo, C.M., Hayden, M.R., and Duta, C. (2018). Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc. Diabetol., 17.","DOI":"10.1186\/s12933-018-0750-8"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.redox.2017.06.009","article-title":"The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats","volume":"13","author":"Steven","year":"2017","journal-title":"Redox Biol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12933-018-0708-x","article-title":"SGLT2 inhibition via dapagliflozin improves generalized vascular dysfunction and alters the gut microbiota in type 2 diabetic mice","volume":"17","author":"Lee","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Terasaki, M., Hiromura, M., Mori, Y., Kohashi, K., Nagashima, M., Kushima, H., Watanabe, T., and Hirano, T. (2015). Amelioration of hyperglycemia with a sodium-glucose cotransporter 2 inhibitor prevents macrophage-driven atherosclerosis through macrophage foam cell formation suppression in type 1 and type 2 diabetic mice. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0143396"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1177\/1479164117733626","article-title":"Dapagliflozin attenuates human vascular endothelial cell activation and induces vasorelaxation: A potential mechanism for inhibition of atherogenesis","volume":"15","author":"Gaspari","year":"2018","journal-title":"Diabetes Vasc. Dis. Res."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE \u2212\/\u2212 mice fed a western diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","article-title":"Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice","volume":"17","author":"Dimitriadis","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 Inhibition with dapagliflozin reduces the activation of the Nlrp3\/ASC Inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc. Drugs"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1161\/CIRCULATIONAHA.119.042929","article-title":"Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction","volume":"140","author":"Nassif","year":"2019","journal-title":"Circulation"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Bhatt, D.L., Szarek, M., Pitt, B., Cannon, C.P., Leiter, L.A., McGuire, D.K., Lewis, J.B., Riddle, M.C., Inzucchi, S.E., and Kosiborod, M.N. (2020). Sotagliflozin in patients with diabetes and chronic kidney disease. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2030186"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Bhatt, D.L., Szarek, M., Steg, P.G., Cannon, C.P., Leiter, L.A., McGuire, D.K., Lewis, J.B., Riddle, M.C., Voors, A.A., and Metra, M. (2020). Sotagliflozin in patients with diabetes and recent worsening heart failure. N. Engl. J. Med.","DOI":"10.1056\/NEJMoa2030183"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.13492","article-title":"Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.114.301621","article-title":"PCSK9: A key modulator of cardiovascular health","volume":"114","author":"Seidah","year":"2014","journal-title":"Circ. Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat. Genet."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat. Genet."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41574-018-0110-5","article-title":"Inhibiting PCSK9\u2014Biology beyond LDL control","volume":"15","author":"Stoekenbroek","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/cvr\/cvz003","article-title":"Novel strategies to target proprotein convertase subtilisin kexin 9: Beyond monoclonal antibodies","volume":"115","author":"Seidah","year":"2019","journal-title":"Cardiovasc. Pathol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1073\/pnas.0335507100","article-title":"The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation","volume":"100","author":"Seidah","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","article-title":"PCSK9 from basic science discoveries to clinical trials","volume":"122","author":"Shapiro","year":"2018","journal-title":"Circ. Res."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1093\/cvr\/cvy128","article-title":"PCSK9 expression in the ischemic heart and its relationship to infarct size, cardiac function, and development of autophagy","volume":"114","author":"Ding","year":"2018","journal-title":"Cardiovasc. Res."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrd3699","article-title":"The biology and therapeutic targeting of the proprotein convertases","volume":"11","author":"Seidah","year":"2012","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOL.0000000000000114","article-title":"PCSK9 and LDLR degradation: Regulatory mechanisms in circulation and in cells","volume":"25","author":"Lagace","year":"2014","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/jcp.22130","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterol metabolism in liver cells","volume":"224","author":"Lan","year":"2010","journal-title":"J. Cell. Physiol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1002\/jcp.27254","article-title":"PCSK9: A novel inflammation modulator in atherosclerosis?","volume":"234","author":"Tang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/cvr\/cvv178","article-title":"Cross-Talk between LOX-1 and PCSK9 in vascular tissues","volume":"107","author":"Ding","year":"2015","journal-title":"Cardiovasc. Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/cvr\/cvz313","article-title":"PCSK9 and inflammation: Role of shear stress, pro-inflammatory cytokines, and LOX-1","volume":"116","author":"Ding","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/path.4630","article-title":"Local effects of human PCSK9 on the atherosclerotic lesion","volume":"238","author":"Giunzioni","year":"2016","journal-title":"J. Pathol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.atherosclerosis.2017.04.023","article-title":"New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4\/NF-\u03baB pathway","volume":"262","author":"Tang","year":"2017","journal-title":"Atherosclerosis"},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Guo, Y., Yan, B., Gui, Y., Tang, Z., Tai, S., Zhou, S., and Zheng, X.L. (2020). Physiology and role of PCSK9 in vascular disease: Potential impact of localized PCSK9 in vascular wall. J. Cell. Physiol.","DOI":"10.1002\/jcp.30025"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis","volume":"62","author":"Urban","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/CIRCULATIONAHA.111.057406","article-title":"Gene inactivation of proprotein convertase subtilisin\/kexin type 9 reduces atherosclerosis in mice","volume":"125","author":"Denis","year":"2012","journal-title":"Circulation"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejmech.2018.11.011","article-title":"Small Molecules as Inhibitors of PCSK9: Current Status and Future Challenges","volume":"162","author":"Xu","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.tcm.2019.05.007","article-title":"The PCSK9 Revolution: Current Status, Controversies and Future Directions: The PCSK9 Revolution","volume":"30","author":"Warden","year":"2020","journal-title":"Trends Cardiovasc. Med."},{"key":"ref_151","doi-asserted-by":"crossref","unstructured":"Nishikido, T., and Ray, K.K. (2019). Non-antibody approaches to proprotein convertase subtilisin kexin 9 inhibition: SiRNA, antisense oligonucleotides, adnectins, vaccination, and new attempts at small-molecule inhibitors based on new discoveries. Front. Cardiovasc. Med., 5.","DOI":"10.3389\/fcvm.2018.00199"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1194\/jlr.M051326","article-title":"Alirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin","volume":"55","author":"Pieterman","year":"2014","journal-title":"J. Lipid Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"9820","DOI":"10.1073\/pnas.0903849106","article-title":"A proprotein convertase subtilisin\/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates","volume":"106","author":"Chan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"11090","DOI":"10.1074\/jbc.M111.319764","article-title":"Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9","volume":"287","author":"Liang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Grefhorst","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1161\/CIRCULATIONAHA.118.038840","article-title":"Effect of alirocumab on mortality after acute coronary syndromes: An analysis of the ODYSSEY OUTCOMES randomized clinical trial","volume":"140","author":"Steg","year":"2019","journal-title":"Circulation"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","article-title":"Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol","volume":"376","author":"Ray","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pathol.2018.10.012","article-title":"PCSK9: From biology to clinical applications","volume":"51","author":"Blanchard","year":"2019","journal-title":"Pathology"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/14712598.2017.1305354","article-title":"Alirocumab for the treatment of hypercholesterolemia","volume":"17","author":"Tomlinson","year":"2017","journal-title":"Expert Opin. Biol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s40262-017-0620-7","article-title":"Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor","volume":"57","author":"Kasichayanula","year":"2018","journal-title":"Clin. Pharm."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","article-title":"Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans","volume":"135","author":"Pavlyha","year":"2017","journal-title":"Circulation"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jjcc.2017.07.002","article-title":"PCSK9 inhibition in the management of familial hypercholesterolemia","volume":"71","author":"Ogura","year":"2018","journal-title":"J. Cardiol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2217\/fca-2018-0067","article-title":"Inclisiran for the treatment of cardiovascular disease: The ORION clinical development program","volume":"14","author":"Stoekenbroek","year":"2018","journal-title":"Future Cardiol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N. Engl. J. Med."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/2\/660\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:09:48Z","timestamp":1760159388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/2\/660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":170,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,1]]}},"alternative-id":["ijms22020660"],"URL":"https:\/\/doi.org\/10.3390\/ijms22020660","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]}}}